Details for New Drug Application (NDA): 219757
✉ Email this page to a colleague
NDA 219757 describes VOSTALLY, which is a drug marketed by Rosemont Pharms and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the VOSTALLY profile page.
The generic ingredient in VOSTALLY is ramipril. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
The generic ingredient in VOSTALLY is ramipril. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
Summary for 219757
| Tradename: | VOSTALLY |
| Applicant: | Rosemont Pharms |
| Ingredient: | ramipril |
| Patents: | 1 |
Pharmacology for NDA: 219757
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for 219757
Suppliers and Packaging for NDA: 219757
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VOSTALLY | ramipril | SOLUTION;ORAL | 219757 | NDA | Rosemont Pharmaceuticals LLC | 69528-303 | 69528-303-05 | 1 BOTTLE, GLASS in 1 CARTON (69528-303-05) / 150 mL in 1 BOTTLE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Jul 23, 2025 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Aug 16, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | VOSTALLY IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE | ||||||||
Complete Access Available with Subscription
